Overview
The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass
Status:
Completed
Completed
Trial end date:
2013-09-01
2013-09-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The study is being undertaken to understand how a gastric bypass can affect a subject's diabetes even prior to their losing significant amounts of weight. The hypothesis of this study is that increased glucagon-like peptide-1 (GLP-1) secretion explains the amelioration in insulin secretion after Roux-en-Y Gastric Bypass (RYGB) surgery.Phase:
Early Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Adrian VellaCollaborators:
National Center for Research Resources (NCRR)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Treatments:
Gastric Inhibitory Polypeptide
Hormones
Incretins
Criteria
Inclusion Criteria:- Subjects with type 2 diabetes mellitus or impaired fasting glucose concentration of >
110 mg/dL
- Subjects registered to receive a Roux-en-Y Gastric Bypass (RYGB).
Exclusion Criteria:
- Subjects taking thiazolidinediones
- Subjects with active systemic illness
- Subjects with active microvascular or macrovascular complications of their diabetes
- For female subject: positive pregnancy test at the time of enrollment in study